Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Overall objective response measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Source null

→

secondary · POSTED

will be assessed by both MRI and by pathologic review after surgery. An estimate of each response rate and the 95% CI will be provided

No data is available because data was not collected due to lack of accrual.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id: NCT01418001
trial label: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id
NCT01418001
outcome key
om-0000
source section id
NCT01418001-om-0000
source outcome index
0
endpoint
Overall Objective Response
endpoint definition
Overall objective response measured using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
time origin
Every 6 weeks up to 2 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id
NCT01418001
outcome key
om-0001
source section id
NCT01418001-om-0001
source outcome index
1
endpoint
Pathologic Response
endpoint definition
will be assessed by both MRI and by pathologic review after surgery. An estimate of each response rate and the 95% CI will be provided
time origin
2 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
No data is available because data was not collected due to lack of accrual.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id
NCT01418001
outcome key
om-0000
arm key
OG000
arm label
Level 1: Pazopanib 400 mg QD
regimen
Level 1: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01418001-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id
NCT01418001
outcome key
om-0001
arm key
OG000
arm label
Pazopanib 400 mg QD
regimen
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib
analyzed count
0
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01418001-om-0001#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-adult-malignant-peripheral-nerve-sheath-tumor
nct id
NCT01418001
harm key
EG000
source section id
NCT01418001-ae
event group key
EG000
event group label
Level 1: Pazopanib 400 mg QD
serious affected
3
serious at risk
5
other affected
5
other at risk
5
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice